Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc. | Soquelitinib - (CPI-818) | Autoimmune Lymphoproliferative Syndrome (ALPS) | Phase 2 | Ongoing | oral | Immunology |
| COSCIENS Biopharma Inc. | Zoptrex | Endometrial cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| COSCIENS Biopharma Inc. | MACRILEN (Macimorelin Acetate) - (DETECT AEZS-130-P02) | Pediatric patients with suspected growth hormone deficiency (GHD) | Phase 3 | Data Released | Oral | Growth Disorder |
| COSCIENS Biopharma Inc. | Avenanthramides Tablets (Avs) | Anti-Inflammatory | Phase 2a | Trial Planned | Oral | N/A |
| Coya Therapeutics Inc. | COYA 302 - (ALSTARS) | Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Enrollment Initiation | Intravenous | Neurology |
| Crinetics Pharmaceuticals Inc. | Atumelnant - (BALANCE-CAH) | Congenital adrenal hyperplasia (CAH) in children and adolescents. | Phase 2/3 | Ongoing | Oral | Endocrinology |
| Crinetics Pharmaceuticals Inc. | Paltusotine - (PATHFNDR-1) | Acromegaly | Phase 3 | Data Released | Oral | Endocrinology |
| Crinetics Pharmaceuticals Inc. | Paltusotine - (PATHFNDR-1) | Acromegaly | Phase 3 | Data Released | Oral | Endocrinology |
